MabThera/Rituxan

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

Roche has seen revenues from blockbuster MabThera/Rituxan slashed in half in Europe thanks to growing biosimilar competition in the second quarter.

Celgene’s Revlimid gets a win in late-stage lymphoma

Patients on Revlimid and Roche’s Rituxan saw boosted PFS rates. Celgene has new phase III data that could add yet another string to blockbuster Revlimid’s bow – as a treatment ... a significant increase in progression-free survival (PFS) compared

Roche keeps Venclexta train rolling with new leukaemia filing

population was expanded after the regulator okayed its use alongside Roche’s Rituxan (rituximab) for all relapsed/refractory CLL patients based on the MURANO trial results.

CTI slumps as Servier-partnered lymphoma drug fails

The PIX306 trial paired Pixuvri (pixantrone) – already sold in some European markets as a monotherapy for hard-to-treat NHL – with Roche’s MabThera (rituximab) and compared it to MabThera plus

AbbVie, Roche get FDA OK for broader use of Venclexta

now also be used in patients without that mutation, both alone and in combination with Rituxan. ... A similar marketing application is under review by the EMA. In MURANO, giving first-in-class BCL-2-targeting drug Venclexta (venetoclax) with anti-CD20

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]